Clinical Trial Search

Primary: Modulation of Levels of Total Haemoglobin — 1.9; 2.4; 1.2 µmol/L — p=>0.05

Primary: Chronic Modulation of Cerebral Blood Flow — 0; 0 Participants — p=>0.05

Primary: Number of Adverse Events — 355; 302 number of AEs

Primary: Percent Change in Brachial Artery Flow-mediated Dilation at Each Time Point — 4.11; 6.93; 5.86; 3.20 Percent Change

Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002

Primary: Change From Baseline in Mitochondrial Respiration in Muscle — -3.05; -4.82; -4.56 nmol O2/s/mg wwt

Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude

Primary: Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events. — 1.57; 1.24 AST/ALT ratio

Primary: Change From Baseline Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score — 6.86; 1.29 standard score change

Primary: Modulation of Levels of Total Haemoglobin — -1.4; -1.3; -1.7 μmol/L — p=<0.05

Primary: Post Meal Glucose Area Under the Curve — 508; 513 mg*hr/dL

Primary: Change in Total HDRS-17 Score From Baseline to Week 4 — -7.2; -9.9 score on a scale

Primary: Walking Speed — -0.04; -0.03; 0.04 m/s

Primary: Cognitive Scores at Baseline and Week 12 — 96; 99; 101; 103 score on a scale

Primary: Change in Hippocampal-dependent Learning — -.00369; .00404 learning rate (proportion correct/trial) — p=<.05

Primary: CBV-fMRI (Cerebral Blood Volume-functional Magnetic Resonance Imaging) — 3.43; 2.55; 2.89; 3.38 percent CBV in a brain region — p=.0001

Primary: Change in Trail Making Test (TMT) B Between Baseline and End of Treatment — -17.63; 3.46 seconds — p=0.0000

Primary: Delay Eyeblink Conditioning — 52.32; 56.88 percentage of conditioned responses

Primary: Systolic Blood Pressure — 116.3; 98.0 mmHg

Primary: fMRI Measurement — 2267.0; 1491.23; 673.31; 989.19 voxels

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: % Change of Brachial Artery Flow-mediated Dilation — 1.3; 0.91 %change

Primary: Correct Responses on Serial 7 Subtraction Task — 40.91; 42.57; 43.04; 42.13 Correct responses — p=0.05

Primary: Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks. — 6.573; 7.272…

Primary: Reaction Time — 402.7; 400; 426.4; 406.6 milliseconds

Primary: Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score) — 39.46; 41.23; 43.1; 50.9 T-score

Primary: Change in Total Fluid Cognitive Score — 6.14; 3.71; 106.06; 105.85 score on a scale

Primary: Cerebral Blood Flow — 48.54; 36.17 ml/min/100g tissue — p=<0.05

Primary: Triglycerides Levels at Week 12 — 210.6; 235.8 mg/dL — p=0.131

Primary: Neuropsychological Performance in Neuropsychological Test: Verbal Learning Memory Test (VLMT) — 57.2; 57.2 score on a scale — p=0.74